Maria Rubinstein/X
Mar 17, 2025, 14:12
Findings from DB-1305/BNT325 by Maria Rubinstein – Moffitt Cancer Center
Moffitt Cancer Center shared a post on X:
“At the SGOMtg plenary session, Maria Rubinstein, MD from Memorial Sloan Kettering Cancer Center shares findings from DB-1305/BNT325 (a novel TROP-2 ADC) in patients with ovarian cancer and highlights encouraging efficacy with a manageable safety profile.
Conclusions:
- DB-1305/BNT325 showed encouraging durable antitumor activity with ORR of 41.4%, DCR of 82.8%, mDOR of 7.3 months, and mPFS of 7.4 months (overall population; N=58).
- In 3 mg/kg (n=30): ORR of 40.0%, DCR of 80.0%, mDOR of 7.3 months, and mPFS of 7.4 months.
- DB-1305/BNT325 was generally well tolerated: stomatitis was the most common TRAE; both overall and Grade 3 events increased with higher doses in patients with ovarian cancer and in the overall population.
- Data support further global clinical development.
- Available clinical efficacy, safety, PK, and E-R analyses support further evaluation of DB-1305/BNT325 at 3 mg/kg Q3W in patients with platinum-resistant ovarian cancer.
- Study is ongoing and will evaluate the combination with BNT327, an anti-PD-L1 x VEGF-A bispecific antibody, which has shown early efficacy in patients with ovarian cancer.
- DB-1305/BNT325 demonstrated encouraging durable efficacy and a manageable safety profile in patients with previously treated ovarian cancer.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 17, 2025, 14:12
Mar 17, 2025, 13:53
Mar 17, 2025, 13:00
Mar 17, 2025, 12:54
Mar 17, 2025, 12:42
Mar 17, 2025, 12:42
Mar 17, 2025, 12:33